The stock of X4 Pharmaceuticals Inc. (NASDAQ:XFOR) decreased by -$0.03 on Monday to finish at $1.25, down -2.34 percent. The last five days have seen an average of 7,594,740 shares of common stock traded. 23 times new highs were reached in the current year, with a gain of $0.2570. The average number of shares traded over the last 20 days was 3,296,720, while the average volume over the last 50 days totaled 3,280,612.
XFOR stock dropped -33.51% since last month. On 08/11/23, the company’s shares reached a one-month low of $0.9500. The stock touched a high of $2.58 on 06/13/23, after rallying from a low of $0.65 in 52 weeks. The price of XFOR stock has risen by 25.88% or $0.2570 this year, reaching a new high 23 times. Still, the stock price is down -51.46% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
XFOR stock investors should be aware that X4 Pharmaceuticals Inc. (XFOR) stock had its last reported insider trading activity 5 days ago on Aug 10. On Aug 10, Interim Chief Medical Officer Stewart Murray sold 130,056 shares at $1.06 each. This transaction resulted in the insider making $137,859. On Jun 30, Mostafa Adam S. sold 2,641 shares at a price of US$1.89. After the transaction, the insider now owns 80,221 shares. Chief Operating Officer DiBiase Mary had earlier sold 464 shares on Jun 30 for $1.89 a share. The transaction was completed for $877.
Financial Health
For the three months ended June 29, X4 Pharmaceuticals Inc.’s quick ratio was 5.00, while its current ratio was 5.00, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 0.62, and the total debt to equity ratio is 0.63. Based on annual data, it had gross profit of $87.57 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. XFOR’s return on assets (ROA) during the last 12 months has been -81.30%. In the meantime, the return on equity (ROE) for the last 12 months was -177.20%.
Earnings Surprise
According to X4 Pharmaceuticals Inc.’s quarterly financial report for the quarter that ended June 29, it had $4.88 million in cash and short-term investments. A lower net income was reported in the quarter under review than the previous quarter. It was predicted that X4 Pharmaceuticals Inc.’s quarterly earnings would be -$0.33, but it ended up being -$0.16, beating the consensus by -106.20%. EBITDA was -$25.68 million for the quarter. At the end of X4 Pharmaceuticals Inc.’s most recent quarter ended June 29, its liabilities totaled 105.86 million, while its total debt was $36.87 million. Equity owned by shareholders amounts to $164.43 million.
Technical Picture
Here’s a quick look at X4 Pharmaceuticals Inc.’s (XFOR) price momentum from a technical perspective. As of 14 August, the RSI 9-day stood at 31.43%, suggesting the stock is Neutral, with a 253.75% historical volatility rate.
The stochastic %K and %D were 24.47% and 18.08% respectively, while the average true range (ATR) was 0.1915. Based on the 14-day stochastic reading of 32.26%, the RSI (14) reading is 33.55%. On the 9-day MACD Oscillator, the stock is at -0.3478, and the 14-day reading is at -0.4274.
Analyst Ratings
In its analyst report released on December 22, 2022, Cantor Fitzgerald began covering X4 Pharmaceuticals Inc. (NASDAQ: XFOR). The stock was rated as an Overweight by the brokerage firm. Analysts have assigned X4 Pharmaceuticals Inc. (XFOR) an Buy rating. XFOR is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 8 others recommend it as a buy.
What is XFOR’s price target for the next 12 months?
The current consensus forecast for the stock is between $2.60 and $5.00, with a median target price of $3.50. In analyzing these forecasts, the average price target given by analysts for X4 Pharmaceuticals Inc. (XFOR) is $3.64.
